CAS: 33674-97-4; (6-Chloropyridin-2-yl)Methanol

相似化合物

83782-89-2 6636-55-1 54087-03-5

上下游产品

CAS号6636-55-1 2-氯吡啶-6-甲酸甲酯 | CAS号18368-63-3 2-氯-6-甲基吡啶 | CAS号86209-84-9 2-acetoxymethyl... | CAS号4684-94-0 6-氯吡啶-2-羧酸 | CAS号52313-59-4 2-氯-6-甲基吡啶 1-氧化物 | CAS号78846-88-5 2-氯-6-氯甲基吡啶 | CAS号78846-88-5 2-氯-6-氯甲基吡啶 | CAS号75279-60-6 6-氯-2-吡啶乙腈 | CAS号54087-03-5 6-氯-2-吡啶甲醛 | CAS号208111-00-6 6-(2-噻吩基)-2-吡啶醛 | CAS号78152-53-1 2-chloro-6(dich... | CAS号933734-79-3 2-(6-chloropyri...

📜6-氯吡啶-2-羧酸置于sodium Tetrahydroborate,乙醇,硫酸体系中,化学反应 41.0H,反应生成 6-氯-2-羟甲基吡啶
参考文献:N-(吡啶甲基)四烷基铵盐的碱诱导 Sommelet-Hauser 重排
标题:N-(吡啶甲基)四烷基铵盐的碱诱导 Sommelet-Hauser 重排
摘要:研究了各种类型的n-(吡啶基甲基) 四烷基铵盐2的碱诱导 Sommelet-Hauser (S-H) 重排以产生n,N-二烷基-α-吡啶基氨基酸酯4.例如,在-40 oc 下,在 Thf中用 1.2 当量的叔丁醇钾处理n-(2-吡啶基甲基)甘氨酸叔丁酯衍生的四烷基铵盐2A,得到相应的 S-H 产物,叔丁基 2-(二甲氨基)-2-(2-甲基吡啶-3-基)乙酸酯(4A),产率为 93%.我们的方法是在简单温和的条件下对吡啶进行有效的 C-H 官能化.
DOI:10.1016/j.Tet.2022.132721

专利信息

专利号:US-7919627-B2
优先权日:2005-05-02
标题:Processes for the preparation of hydroxylamines
发明人：TANG DATONG; QIU YAO-LING; KIM HEEJIN; OR YAT SUN; WANG ZHE
权利人:ENANTA PHARM INC
摘要:The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (Ia):

专利号:US-5084458-A
优先权日:1987-05-14
标 题 :Substituted 2-acylpyridine-β-(N)-hetaryl-hydrazones and medicaments containing the same
发明人：SCHAPER KLAUS-JUERGEN; SEYDEL JOACHIM K
权利人:SCHAPER KLAUS JUERGEN; SEYDEL JOACHIM K
摘要:PCT No. PCT/DE88/00289 Sec. 371 Date Mar. 7, 1989 Sec. 102(e) Date Mar. 7, 1989 PCT Filed May 14, 1988 PCT Pub. No. WO88/08842 PCT Pub. Date Nov. 17, 1988.Substituted 2-acylpyridine- alpha -(N)-hetarylhydrazones are described, which are suitable as active substances for the treatment of antimicrobial and in particular antimycobacterial diseases, as well as active substances for the treatment of malaria or malignant tumours. The compounds have a marked synergistic activity combined with inhibitors of folate synthase, dihydrofolic acid reductase, DNA-synthesis and RNA-synthesis.